We are looking for a Scientific Program Manager for our new Neuroimmune Post-Acute Infection Syndrome Program 📣 We are seeking a PhD-level Scientific Program Manager to serve as the program's operational and administrative backbone. Please apply/spread the word 🙏🏼
Lindsay McAlpine MD, (@McAlpineLabYale) a neuroimmunologist @YaleMed, spoke with @NBCConnecticut about #MECFS and her role as an investigator in BioVie’s Phase 2 ADDRESS-LC #clinicaltrial evaluating bezisterim for the treatment of the neurological symptoms of #LongCOVID.
Watch here: https://t.co/mEWPkTrnY1
📢 BREAKING NEWS: It was announced today that the NIH-RECOVER Autonomic trial of IVIG in 200 patients with post-COVID POTS vs. IV saline showed "no significant impact of IVIG on symptoms of severe POTS."
Details of the trial are not available yet, but results are a major setback for patients with disabling post-COVID POTS waiting for treatment.
https://t.co/GOW7JMRtCn
Calling folks in the Northeast! We’re recruiting individuals with Long COVID and brain fog or cognitive difficulties for a Yale research study involving an MRI with gadolinium contrast. See the flyer for details, and please share! #longcovid
Bringing awareness to ME/Chronic Fatigue Syndrome! I was so happy to talk to @NBCConnecticut this month about this condition, Long COVID, and the research we are doing #mecfs@NeurologyYale@YaleMed
https://t.co/l6dzDy7YFn
Calling folks in the Northeast! We’re recruiting individuals with Long COVID and brain fog or cognitive difficulties for a Yale research study involving an MRI with gadolinium contrast. See the flyer for details, and please share! #longcovid
Thanks to @BrainInflCollab for discussing my papers on #POTS, #MECFS and #LongCOVID as neuroimmune disorders and a possible CNS localization of POTS/dysautonomia to the dorsolateral medulla! 🧠
Read more about these emerging topics here:
https://t.co/qsZet122NQ
https://t.co/Y78T90z2MB
#COVID19:
🟢 Prevent yourself from getting sick
🟢 Stay protected, especially if you are at higher risk of severe illness
🟢 Prevent spreading it to others if you do get sick
So incredibly excited BioVie announced the positive results from our Phase 2 ADDRESS-LC trial of bezisterim in Long COVID and proud to have contributed! Thank you to our wonderful participants @BioVie_Pharma#LongCOVID
https://t.co/EdpETeycgL
My patients often report improvement with GLP-1 RAs. Today one patient with #dysautonomia/#MCAS told me she is back to running after starting GLP-1 RA. 🏃♀️
📢 Our paper on post-COVID vaccination dysautonomia improving after GLP-1 RA was just published!
https://t.co/M4EP0Kzc4w
So incredibly excited BioVie announced the positive results from our Phase 2 ADDRESS-LC trial of bezisterim in Long COVID and proud to have contributed! Thank you to our wonderful participants @BioVie_Pharma#LongCOVID
https://t.co/EdpETeycgL
Today, we announced positive results from our Phase 2 signal finding ADDRESS-LC trial evalulating bezisterim for the treatment of neurological symptoms associated with Long COVID. Read: https://t.co/o1uMEs8BE3
$BIVI
Long COVID patients still lack access to specialized rehab. We urgently need disease-modifying therapies and individualized cognitive rehabilitation should become a standard part of care—just as it is for TBI and MS. #LongCOVID https://t.co/anO47frA2J
'STORM' is a short documentary about Scott Hugo. A story of Long COVID's impact on his life and family - a reminder of what is at stake in research on Long COVID.
His resilience humbles me.
Please watch and share 🙏🏼
https://t.co/tN7B5wcq2I